NASDAQ:PIRS Pieris Pharmaceuticals (PIRS) Stock Price, News & Analysis → AI Cracks Open Largest Untapped Energy Reserve on Earth (From Banyan Hill Publishing) (Ad) Free PIRS Stock Alerts $0.21 +0.04 (+23.53%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$0.18▼$0.2850-Day Range$0.16▼$0.2152-Week Range$0.14▼$1.52Volume9.49 million shsAverage Volume501,129 shsMarket Capitalization$20.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Pieris Pharmaceuticals alerts: Email Address Pieris Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.07% of Shares Sold ShortDividend StrengthN/ASustainability-0.95Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.35) to ($0.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.59 out of 5 starsMedical Sector518th out of 947 stocksPharmaceutical Preparations Industry242nd out of 435 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Pieris Pharmaceuticals. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.07% of the outstanding shares of Pieris Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverPieris Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pieris Pharmaceuticals has recently increased by 6.80%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPieris Pharmaceuticals does not currently pay a dividend.Dividend GrowthPieris Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePieris Pharmaceuticals has received a 69.14% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Pieris Pharmaceuticals is -0.95. Previous Next 3.9 News and Social Media Coverage News SentimentPieris Pharmaceuticals has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Pieris Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest3 people have searched for PIRS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows6 people have added Pieris Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pieris Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.89% of the stock of Pieris Pharmaceuticals is held by insiders.Percentage Held by Institutions75.03% of the stock of Pieris Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Pieris Pharmaceuticals are expected to grow in the coming year, from ($0.35) to ($0.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pieris Pharmaceuticals is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pieris Pharmaceuticals is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPieris Pharmaceuticals has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyMy next big prediction isn’t a predictionI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.Click here now to sign up About Pieris Pharmaceuticals Stock (NASDAQ:PIRS)Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.Read More PIRS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PIRS Stock News HeadlinesMarch 12, 2024 | americanbankingnews.comPieris Pharmaceuticals (NASDAQ:PIRS) Earns Hold Rating from Analysts at StockNews.comFebruary 10, 2024 | investing.comPieris Pharmaceuticals Inc (PIRS)March 18, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.February 1, 2024 | finance.yahoo.comPieris Pharmaceuticals, Inc. (PIRS)December 18, 2023 | finance.yahoo.comInvestors Don't See Light At End Of Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Tunnel And Push Stock Down 27%November 20, 2023 | investing.comPieris Pharmaceuticals Inc (PIRS) Earnings Dates & ReportsNovember 4, 2023 | morningstar.comPieris Pharmaceuticals Inc PIRSSeptember 25, 2023 | finance.yahoo.comPieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's WhyMarch 18, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.August 24, 2023 | finance.yahoo.comIs Pieris Pharmaceuticals (PIRS) a Value Trap? A Comprehensive AnalysisAugust 23, 2023 | finance.yahoo.comPieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should KnowAugust 18, 2023 | msn.comPieris (PIRS) Up On Receiving Milestone Payment From PartnerAugust 17, 2023 | finance.yahoo.comPieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology BispecificJuly 19, 2023 | finance.yahoo.comPieris (PIRS) Pursues Strategic Alternatives, Stock RisesJuly 19, 2023 | markets.businessinsider.comPieris Pharma Cuts Around 70% Workforce; Plans Strategic OptionsJuly 18, 2023 | finanznachrichten.dePieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Provides Strategic Update and Announces RestructuringJuly 18, 2023 | finance.yahoo.comWhy Pieris Pharmaceuticals Shares Shooting Higher Today?July 18, 2023 | finance.yahoo.comPieris Pharmaceuticals Provides Strategic Update and Announces RestructuringJuly 13, 2023 | fool.comPieris Pharmaceuticals (NASDAQ: PIRS)June 21, 2023 | msn.comWhy Are Pieris Pharmaceuticals Shares Tanking TodayJune 21, 2023 | finance.yahoo.comPieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology StudyJune 11, 2023 | finance.yahoo.comWe're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn RateJune 2, 2023 | finanznachrichten.dePieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare ConferenceJune 2, 2023 | finance.yahoo.comPieris Pharmaceuticals to Present at Jefferies 2023 Healthcare ConferenceMay 22, 2023 | finance.yahoo.comPieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International ConferenceMay 21, 2023 | finance.yahoo.comPieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International ConferenceMay 15, 2023 | finance.yahoo.comPieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Analysts Just Cut Their EPS Forecasts SubstantiallySee More Headlines Receive PIRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2021Today3/18/2024Next Earnings (Estimated)4/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PIRS CUSIPN/A CIK1583648 Webwww.pieris.com Phone(857) 246-8998Fax49-8161-141-1444Employees127Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,280,000.00 Net Margins-59.25% Pretax Margin-59.25% Return on Equity-98.12% Return on Assets-34.57% Debt Debt-to-Equity RatioN/A Current Ratio2.05 Quick Ratio2.05 Sales & Book Value Annual Sales$25.90 million Price / Sales0.80 Cash FlowN/A Price / Cash FlowN/A Book Value$0.38 per share Price / Book0.55Miscellaneous Outstanding Shares98,850,000Free Float90,064,000Market Cap$20.76 million OptionableOptionable Beta0.48 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Stephen S. Yoder J.D. (Age 48)CEO, President & Director Comp: $774.72kMr. Thomas Bures (Age 50)Senior VP & CFO Comp: $499.38kMaria KelmanExecutive Director of Investor RelationsMr. Frank VollmeringVice President of Human ResourcesDr. Shane Olwill Ph.D. (Age 48)Senior VP & Chief Development Officer Mr. Prompong Chaikul (Age 37)Chief Supply Chain Officer Dr. Florian Witte Ph.D.VP and Head of Alliance Management & Early Project LeadershipMore ExecutivesKey CompetitorsAytu BioPharmaNASDAQ:AYTUIndaptus TherapeuticsNASDAQ:INDPSynlogicNASDAQ:SYBXFortress BiotechNASDAQ:FBIORenovoRxNASDAQ:RNXTView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 128,150 shares on 3/11/2024Ownership: 0.918%Vanguard Group Inc.Sold 128,150 shares on 2/15/2024Ownership: 0.918%Northern Trust CorpBought 105,783 shares on 2/13/2024Ownership: 0.246%Christopher P KiritsyBought 10,000 shares on 5/25/2023Total: $8,500.00 ($0.85/share)View All Insider TransactionsView All Institutional Transactions PIRS Stock Analysis - Frequently Asked Questions Should I buy or sell Pieris Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" PIRS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PIRS, but not buy additional shares or sell existing shares. View PIRS analyst ratings or view top-rated stocks. How have PIRS shares performed in 2024? Pieris Pharmaceuticals' stock was trading at $0.1820 at the beginning of the year. Since then, PIRS shares have increased by 15.4% and is now trading at $0.21. View the best growth stocks for 2024 here. When is Pieris Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024. View our PIRS earnings forecast. How were Pieris Pharmaceuticals' earnings last quarter? Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) issued its earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.24) EPS for the quarter, meeting analysts' consensus estimates of ($0.24). The biotechnology company earned $4.06 million during the quarter, compared to the consensus estimate of $7.98 million. Pieris Pharmaceuticals had a negative net margin of 59.25% and a negative trailing twelve-month return on equity of 98.12%. During the same period in the previous year, the firm earned ($0.26) EPS. What other stocks do shareholders of Pieris Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pieris Pharmaceuticals investors own include Verastem (VSTM), TG Therapeutics (TGTX), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Dynavax Technologies (DVAX), Sangamo Therapeutics (SGMO), Allena Pharmaceuticals (ALNA) and Anavex Life Sciences (AVXL). Who are Pieris Pharmaceuticals' major shareholders? Pieris Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (0.92%), Vanguard Group Inc. (0.92%), Northern Trust Corp (0.25%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Christopher P Kiritsy, Shane Olwill and Tim Demuth. View institutional ownership trends. How do I buy shares of Pieris Pharmaceuticals? Shares of PIRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PIRS) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingBill Gates Bets on $15 Trillion BonanzaWeiss RatingsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pieris Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.